2 weeks Ago By ABMN Staff
Mackenzie Financial Corp raised its holdings in shares of Merck & Co., Inc. ( NYSE:MRK – Free Report ) by 6.
9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,339,106 shares of the company’s stock after acquiring an additional 149,979 shares during the period. Mackenzie Financial Corp owned approximately 0.
09% of Merck & Co., Inc. worth $289,581,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in the stock. Capital International Investors lifted its stake in Merck & Co., Inc.
by 3,714.9% in the first quarter. Capital International Investors now owns 6,023,853 shares of the company’s stock valued at $794,847,000 after buying an additional 5,865,948 shares in the last quarter.
Capital World Investors lifted its position in Merck & Co., Inc. by 67.
6% in the 1st quarter. Capital World Investors now owns 13,954,017 shares of the company’s stock valued at $1,841,233,000 after acquiring an additional 5,627,923 shares in the last quarter. Swedbank AB acquired a new position in Merck & Co.
, Inc. in the 1st quarter worth $724,776,000. Wellington Management Group LLP increased its holdings in Merck & Co.
, Inc. by 3.8% during the 4th quarter.
Wellington Management Group LLP now owns 85,595,999 shares of the company’s stock worth $9,331,676,000 after purchasing an additional 3,153,333 shares in the last quarter. Finally, Wulff Hansen & CO. raised its stake in shares of Merck & Co.
, Inc. by 11,860.9% in the 2nd quarter.
Wulff Hansen & CO. now owns 2,494,199 shares of the company’s stock valued at $308,782,000 after purchasing an additional 2,473,346 shares during the period. Institutional investors and hedge funds own 76.
07% of the company’s stock. Wall Street Analyst Weigh In Several research analysts have recently weighed in on the company. Wolfe Research raised Merck & Co.
, Inc. to a “strong-buy” rating in a research report on Wednesday, July 31st. Wells Fargo & Company reduced their price target on Merck & Co.
, Inc. from $140.00 to $125.
00 and set an “equal weight” rating for the company in a research report on Wednesday, July 31st. Evercore ISI upgraded shares of Merck & Co., Inc.
to a “strong-buy” rating in a report on Tuesday, July 30th. Morgan Stanley increased their target price on shares of Merck & Co., Inc.
from $132.00 to $134.00 and gave the stock an “equal weight” rating in a report on Thursday, July 11th.
Finally, UBS Group lowered their price target on shares of Merck & Co., Inc. from $148.
00 to $142.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and four have issued a strong buy rating to the company.
According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $134.58. Merck & Co.
, Inc. Trading Down 1.4 % Shares of MRK stock opened at $113.
08 on Friday. Merck & Co., Inc.
has a 12-month low of $99.14 and a 12-month high of $134.63.
The company has a market capitalization of $286.41 billion, a PE ratio of 125.64, a price-to-earnings-growth ratio of 1.
60 and a beta of 0.39. The firm has a 50 day moving average price of $116.
95 and a two-hundred day moving average price of $124.06. The company has a quick ratio of 1.
22, a current ratio of 1.47 and a debt-to-equity ratio of 0.80.
Merck & Co., Inc. ( NYSE:MRK – Get Free Report ) last released its quarterly earnings results on Tuesday, July 30th.
The company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.
12. The business had revenue of $16.10 billion during the quarter, compared to the consensus estimate of $15.
87 billion. Merck & Co., Inc.
had a return on equity of 40.69% and a net margin of 21.99%.
The firm’s quarterly revenue was up 7.1% on a year-over-year basis. During the same period in the previous year, the company posted ($2.
06) EPS. As a group, analysts predict that Merck & Co., Inc.
will post 8.01 earnings per share for the current year. Merck & Co.
, Inc. Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be paid a $0.
77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 2.
72%. The ex-dividend date of this dividend is Monday, September 16th. Merck & Co.
, Inc.’s dividend payout ratio (DPR) is currently 342.22%.
Merck & Co., Inc. Company Profile ( Free Report ) Merck & Co, Inc operates as a healthcare company worldwide.
It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. Featured Stories Receive News & Ratings for Merck & Co.
Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc.
and related companies with MarketBeat.com's FREE daily email newsletter ..
